Advantage of using a recombinant activated factor VII in traumatic haemorrhagic shock: The Bordeaux experience

Advantage of using a recombinant activated factor VII in traumatic haemorrhagic shock: The Bordeaux experience

Introduction: Several series of patient studies have been published on the use of rFVIIa in traumatic haemorrhagic shock, although to date no international recommendations have been produced. France does not currently recognise traumatic haemorrhagic shock as an appropriate indication for the use of...

Full description

Bibliographic Details
Main Authors: Nicolas Morel, Cyrille Chabarttier, Laurent Merson, Agathe Lelias, Jean-Christophe Bernard, François Delaunay, Philippe Dabadie, Gérard Janvier
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2012-01-01
Series:Journal of Emergencies, Trauma and Shock
Subjects:
Haemorrhagic shock
trauma
transfusion
rFVIIa
Online Access:http://www.onlinejets.org/article.asp?issn=0974-2700;year=2012;volume=5;issue=2;spage=143;epage=148;aulast=Morel

Internet

http://www.onlinejets.org/article.asp?issn=0974-2700;year=2012;volume=5;issue=2;spage=143;epage=148;aulast=Morel

Similar Items